One-year outcomes of the ARTISAN-SNM study with the Axonics System for the treatment of urinary urgency incontinence.


Journal

Neurourology and urodynamics
ISSN: 1520-6777
Titre abrégé: Neurourol Urodyn
Pays: United States
ID NLM: 8303326

Informations de publication

Date de publication:
06 2020
Historique:
received: 22 01 2020
accepted: 15 04 2020
pubmed: 28 4 2020
medline: 21 11 2020
entrez: 28 4 2020
Statut: ppublish

Résumé

Sacral neuromodulation (SNM) is a guideline-recommended treatment for voiding dysfunction including urgency, urge incontinence, and nonobstructive retention as well as fecal incontinence. The Axonics® System is a miniaturized, rechargeable SNM system designed to provide therapy for at least 15 years, which is expected to significantly reduce revision surgeries as it will not require replacement as frequently as the non-rechargeable SNM system. The ARTISAN-SNM study is a pivotal study designed to treat patients with urinary urgency incontinence (UUI). Clinical results at 1-year are presented. A total of 129 eligible UUI patients were treated. All participants were implanted with a quadripolar tined lead and neurostimulator in a single procedure. Efficacy data were collected using a 3-day bladder diary, a validated quality of life questionnaire (ICIQ-OABqol), and a participant satisfaction questionnaire. Therapy responders were defined as participants with ≥50% reduction in UUI episodes compared to baseline. Data were analyzed on all 129 participants. At 1 year, 89% of the participants were therapy responders. The average UUI episodes per day reduced from 5.6 ± 0.3 at baseline to 1.4 ± 0.2. Participants experienced an overall clinically meaningful improvement of 34 points on the ICIQ-OABqol questionnaire. All study participants (100%) were able to recharge their device at 1 year, and 96% of participants reported that the frequency and duration of recharging was acceptable. There were no serious device-related adverse events. The Axonics System is safe and effective at 1 year, with 89% of participants experiencing clinically and statistically significant improvements in UUI symptoms.

Identifiants

pubmed: 32339339
doi: 10.1002/nau.24376
pmc: PMC7384085
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1482-1488

Subventions

Organisme : Axonics Modulation Technologies
Pays : International

Informations de copyright

© 2020 The Authors. Neurourology and Urodynamics Published by Wiley Periodicals, Inc.

Références

Neurourol Urodyn. 2017 Mar;36(3):727-733
pubmed: 27062384
Neurourol Urodyn. 2014 Jun;33(5):488-92
pubmed: 23737158
Neurourol Urodyn. 2018 Jun;37(5):1823-1848
pubmed: 29641846
Neurourol Urodyn. 2018 Feb;37(S2):S1-S8
pubmed: 29336078
Neuromodulation. 2014 Jul;17(5):425-30; discussion 430
pubmed: 24112630
Neuromodulation. 2012 May-Jun;15(3):214-7; discussion 217-8
pubmed: 22074455
BJU Int. 2019 May;123(5A):E7-E13
pubmed: 30537223
Neuromodulation. 2017 Dec;20(8):836-840
pubmed: 29024404
Br J Neurosurg. 2014 Oct;28(5):645-9
pubmed: 24559123
JAMA Intern Med. 2019 Jun 24;:
pubmed: 31233095
Neurourol Urodyn. 2020 Jun;39(5):1482-1488
pubmed: 32339339
Neurourol Urodyn. 2016 Feb;35(2):246-51
pubmed: 25546568
J Urol. 2020 Jan;203(1):185-192
pubmed: 31347955
Neuromodulation. 2017 Dec;20(8):816-824
pubmed: 28975677
Neurourol Urodyn. 2019 Aug;38(6):1595-1601
pubmed: 31044466
Eur Urol. 2014 Jan;65(1):79-95
pubmed: 24007713
BJU Int. 2011 Oct;108(7):1132-8
pubmed: 21231991
Neurourol Urodyn. 2019 Feb;38(2):689-695
pubmed: 30592526
Rheumatology (Oxford). 2017 Apr 1;56(4):581-588
pubmed: 28013205

Auteurs

Kevin Benson (K)

Sanford Hospital, Sioux Falls, South Dakota.

Rebecca McCrery (R)

Adult and Pediatric Urology and Urogynecology, Omaha, Nebraska.

Chris Taylor (C)

Taylor Surgical Arts, Harrison, Arkansas.

Osvaldo Padron (O)

Florida Urology Partners, Tampa, Florida.

Bertil Blok (B)

Department of Urology, Erasmus MC, Rotterdam, The Netherlands.

Stefan de Wachter (S)

Department of Urology, University Hospital Antwerpen, Edegem, Belgium.

Andrea Pezzella (A)

Southern Urogynecology, West Columbia, South Carolina.

Jennifer Gruenenfelder (J)

Orange County Urology Associates, Laguna Hills, California.

Mahreen Pakzad (M)

Department of Urology, University College London Hospital, Marylebone, London, UK.

Marie-Aimee Perrouin-Verbe (MA)

Department of Urology, CHU de Nantes Hotel Dieu, Nantes, France.

Philip Van Kerrebroeck (P)

Department of Urology, Maastricht University Medical Centre, Maastricht, The Netherlands.

Jeffrey Mangel (J)

MetroHealth, Cleveland, Ohio.

Kenneth Peters (K)

Beaumont Health, Royal Oak, Michigan.

Michael Kennelly (M)

Carolinas Healthcare System Charlotte, North Carolina.

Andrew Shapiro (A)

Chesapeake Urology Research Associates, Owings Mills, Maryland.

Una Lee (U)

Virginia Mason, Seattle, Washington.

Craig Comiter (C)

Stanford University, Palo Alto, California.

Margaret Mueller (M)

Northwestern University, Chicago, Illinois.

Howard Goldman (H)

Cleveland Clinic, Cleveland, Ohio.

Felicia Lane (F)

University of California, Irvine, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH